Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer
- 1 February 2019
- journal article
- research article
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 38, 62-66
Abstract
No abstract availableKeywords
Funding Information
- “Ljudevit Jurak” Department of Pathology and Cytology, Clinical Hospital Center “Sestre milosrdnice”
This publication has 27 references indexed in Scilit:
- Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine DifferentiationBreast Care, 2012
- Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Somatostatin and Dopamine Receptor Profile of Gastroenteropancreatic Neuroendocrine Tumors: An Immunohistochemical StudyEndocrine Pathology, 2011
- Invasive neuroendocrine carcinoma of the breastCancer, 2010
- SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.Folia Histochemica et Cytobiologica, 2010
- Biology of somatostatin in breast cancerMolecular and Cellular Endocrinology, 2008
- Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathologyBreast Cancer Research and Treatment, 2005
- Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumorsVirchows Archiv, 2002
- A randomized, multicenter prospective trial assessing long‐acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinomaCancer, 2002
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991